Am J Cancer Res 2012;2(2):130-140
Review Article
Modeling follicular thyroid cancer for future therapies
Xuguang Zhu, Sheue-yann Cheng
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute National Institutes of Health, Bethesda,
MD, USA.
Received January 1, 2012; accepted January 19, 2012; Epub February, 2012; Published February 1, 2012
Abstract: Therapeutic choices are limited for undifferentiated metastatic thyroid carcinomas. Although implanted subcutaneous
thyroid tumors are standard preclinical models to examine the efficacy of new therapeutic agents, these xenograft models
frequently fail to predict the outcomes of clinical trials in patients with metastatic thyroid carcinomas. Genetically engineered
mouse models with alterations similar to human cancers in their pathological progression and in an immunocompetent
environment offer unparalleled opportunities for evaluating novel potential molecular targets. We review recent advances in the
modeling of follicular thyroid carcinoma with distant metastasis and in the use of these mouse models in preclinical studies,
emphasizing the significance of genetically engineered mouse models in clinical applications. (AJCR00000100).
Keywords: Thyroid cancer, thyroid hormone receptors, preclinical studies, mouse models, thyroid hormone receptor mutations
Address all correspondence to:
Dr. Sheue-yann Cheng
Laboratory of Molecular Biology
National Cancer Institute
37 Convent Dr, Room 5128
Bethesda, MD 20892-4264, USA.
Tel: (301) 496-4280; Fax: (301) 480-9676
E-mail: chengs@mail.nih.gov
Review Article
Modeling follicular thyroid cancer for future therapies
Xuguang Zhu, Sheue-yann Cheng
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute National Institutes of Health, Bethesda,
MD, USA.
Received January 1, 2012; accepted January 19, 2012; Epub February, 2012; Published February 1, 2012
Abstract: Therapeutic choices are limited for undifferentiated metastatic thyroid carcinomas. Although implanted subcutaneous
thyroid tumors are standard preclinical models to examine the efficacy of new therapeutic agents, these xenograft models
frequently fail to predict the outcomes of clinical trials in patients with metastatic thyroid carcinomas. Genetically engineered
mouse models with alterations similar to human cancers in their pathological progression and in an immunocompetent
environment offer unparalleled opportunities for evaluating novel potential molecular targets. We review recent advances in the
modeling of follicular thyroid carcinoma with distant metastasis and in the use of these mouse models in preclinical studies,
emphasizing the significance of genetically engineered mouse models in clinical applications. (AJCR00000100).
Keywords: Thyroid cancer, thyroid hormone receptors, preclinical studies, mouse models, thyroid hormone receptor mutations
Address all correspondence to:
Dr. Sheue-yann Cheng
Laboratory of Molecular Biology
National Cancer Institute
37 Convent Dr, Room 5128
Bethesda, MD 20892-4264, USA.
Tel: (301) 496-4280; Fax: (301) 480-9676
E-mail: chengs@mail.nih.gov
| AJCR Copyright © 2010-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 | |  | |  | |  | |  | |  | |  | |  |
American Journal of Cancer Research
| ISSN: 2156-6976 |